Cargando…
Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types
Formyl peptide receptor-like 1 inhibitor protein (FLIPr) is an immune evasion protein produced by Staphylococcus aureus, and FLIPr is a potential vaccine candidate for reducing Staphylococcus aureus virulence and biofilm formation. We produced recombinant lipidated FLIPr (rLF) to increase the immuno...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236402/ https://www.ncbi.nlm.nih.gov/pubmed/37268688 http://dx.doi.org/10.1038/s41541-023-00680-4 |
_version_ | 1785052911526477824 |
---|---|
author | Hsieh, Ming-Shu Chen, Mei-Yu Hsu, Chia-Wei Tsai, Yu-Wen Chiu, Fang-Feng Hsu, Cheng-Lung Lin, Chang-Ling Wu, Chiao-Chieh Tu, Ling-Ling Chiang, Chen-Yi Liu, Shih-Jen Liao, Ching-Len Chen, Hsin-Wei |
author_facet | Hsieh, Ming-Shu Chen, Mei-Yu Hsu, Chia-Wei Tsai, Yu-Wen Chiu, Fang-Feng Hsu, Cheng-Lung Lin, Chang-Ling Wu, Chiao-Chieh Tu, Ling-Ling Chiang, Chen-Yi Liu, Shih-Jen Liao, Ching-Len Chen, Hsin-Wei |
author_sort | Hsieh, Ming-Shu |
collection | PubMed |
description | Formyl peptide receptor-like 1 inhibitor protein (FLIPr) is an immune evasion protein produced by Staphylococcus aureus, and FLIPr is a potential vaccine candidate for reducing Staphylococcus aureus virulence and biofilm formation. We produced recombinant lipidated FLIPr (rLF) to increase the immunogenicity of FLIPr and showed that rLF alone elicited potent anti-FLIPr antibody responses to overcome the FLIPr-mediated inhibition of phagocytosis. In addition, rLF has potent immunostimulatory properties. We demonstrated that rLF is an effective adjuvant. When an antigen is formulated with rLF, it can induce long-lasting antigen-specific immune responses and enhance mucosal and systemic antibody responses as well as broad-spectrum T-cell responses in mice. These findings support further exploration of rLF in the clinic as an adjuvant for various vaccine types with extra benefits to abolish FLIPr-mediated immunosuppressive effects. |
format | Online Article Text |
id | pubmed-10236402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-102364022023-06-04 Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types Hsieh, Ming-Shu Chen, Mei-Yu Hsu, Chia-Wei Tsai, Yu-Wen Chiu, Fang-Feng Hsu, Cheng-Lung Lin, Chang-Ling Wu, Chiao-Chieh Tu, Ling-Ling Chiang, Chen-Yi Liu, Shih-Jen Liao, Ching-Len Chen, Hsin-Wei NPJ Vaccines Article Formyl peptide receptor-like 1 inhibitor protein (FLIPr) is an immune evasion protein produced by Staphylococcus aureus, and FLIPr is a potential vaccine candidate for reducing Staphylococcus aureus virulence and biofilm formation. We produced recombinant lipidated FLIPr (rLF) to increase the immunogenicity of FLIPr and showed that rLF alone elicited potent anti-FLIPr antibody responses to overcome the FLIPr-mediated inhibition of phagocytosis. In addition, rLF has potent immunostimulatory properties. We demonstrated that rLF is an effective adjuvant. When an antigen is formulated with rLF, it can induce long-lasting antigen-specific immune responses and enhance mucosal and systemic antibody responses as well as broad-spectrum T-cell responses in mice. These findings support further exploration of rLF in the clinic as an adjuvant for various vaccine types with extra benefits to abolish FLIPr-mediated immunosuppressive effects. Nature Publishing Group UK 2023-06-02 /pmc/articles/PMC10236402/ /pubmed/37268688 http://dx.doi.org/10.1038/s41541-023-00680-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Hsieh, Ming-Shu Chen, Mei-Yu Hsu, Chia-Wei Tsai, Yu-Wen Chiu, Fang-Feng Hsu, Cheng-Lung Lin, Chang-Ling Wu, Chiao-Chieh Tu, Ling-Ling Chiang, Chen-Yi Liu, Shih-Jen Liao, Ching-Len Chen, Hsin-Wei Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types |
title | Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types |
title_full | Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types |
title_fullStr | Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types |
title_full_unstemmed | Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types |
title_short | Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types |
title_sort | recombinant lipidated flipr effectively enhances mucosal and systemic immune responses for various vaccine types |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236402/ https://www.ncbi.nlm.nih.gov/pubmed/37268688 http://dx.doi.org/10.1038/s41541-023-00680-4 |
work_keys_str_mv | AT hsiehmingshu recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT chenmeiyu recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT hsuchiawei recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT tsaiyuwen recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT chiufangfeng recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT hsuchenglung recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT linchangling recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT wuchiaochieh recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT tulingling recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT chiangchenyi recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT liushihjen recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT liaochinglen recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes AT chenhsinwei recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes |